Skip to main content

Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.

Publication ,  Journal Article
Shepherd-Banigan, ME; Ford, CB; Smith, VA; Belanger, E; Wetle, TT; Plassman, BL; Burke, JR; DePasquale, N; O'Brien, EC; Sorenson, C; Van Houtven, CH
Published in: J Alzheimers Dis
2022

BACKGROUND: Diagnostic tests, such as amyloid-β positron emission tomography (PET) scans, can increase appropriate therapeutic management for the underlying causes of cognitive decline. To evaluate the full utility of this diagnostic tool, information is needed on whether results from amyloid-β PET scans influence care-partner outcomes. OBJECTIVE: This study examines the extent to which previous disclosure of elevated amyloid (suggestive of Alzheimer's disease (AD) etiology) versus not-elevated amyloid (not suggestive of AD etiology) is associated with changes in care-partner wellbeing. METHODS: The study used data derived from a national longitudinal survey of Medicare beneficiaries (n = 921) with mild cognitive impairment (MCI) or dementia and their care-partners. Care-partner wellbeing outcomes included depressive symptoms (PHQ-8), subjective burden (4-item Zarit burden score), and a 3-item measure of loneliness. Change was measured between 4 (Time 1) and 18 (Time 2) months after receiving the scan results. Adjusted linear regression models regressed change (Time 2-Time 1) in each outcome on scan result. RESULTS: Care-partners were primarily white, non-Hispanic, college-educated, and married to the care recipient. Elevated amyloid was not associated with statistically significant Time 1 differences in outcomes or with statistically significant changes in depressive symptoms 0.22 (-0.18, 0.61), subjective burden 0.36 (-0.01, 0.73), or loneliness 0.15 (-0.01, 0.32) for care-partners from one time point to another. CONCLUSION: Given advances in AD biomarker testing, future research in more diverse samples is needed to understand the influence of scan results on care-partner wellbeing across populations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Alzheimers Dis

DOI

EISSN

1875-8908

Publication Date

2022

Volume

90

Issue

2

Start / End Page

775 / 782

Location

Netherlands

Related Subject Headings

  • United States
  • Positron-Emission Tomography
  • Neurology & Neurosurgery
  • Medicare
  • Humans
  • Disclosure
  • Cognitive Dysfunction
  • Amyloidosis
  • Amyloid beta-Peptides
  • Amyloid
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shepherd-Banigan, M. E., Ford, C. B., Smith, V. A., Belanger, E., Wetle, T. T., Plassman, B. L., … Van Houtven, C. H. (2022). Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time. J Alzheimers Dis, 90(2), 775–782. https://doi.org/10.3233/JAD-220611
Shepherd-Banigan, Megan E., Cassie B. Ford, Valerie A. Smith, Emmanuelle Belanger, Terrie T. Wetle, Brenda L. Plassman, James R. Burke, et al. “Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.J Alzheimers Dis 90, no. 2 (2022): 775–82. https://doi.org/10.3233/JAD-220611.
Shepherd-Banigan ME, Ford CB, Smith VA, Belanger E, Wetle TT, Plassman BL, et al. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time. J Alzheimers Dis. 2022;90(2):775–82.
Shepherd-Banigan, Megan E., et al. “Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time.J Alzheimers Dis, vol. 90, no. 2, 2022, pp. 775–82. Pubmed, doi:10.3233/JAD-220611.
Shepherd-Banigan ME, Ford CB, Smith VA, Belanger E, Wetle TT, Plassman BL, Burke JR, DePasquale N, O’Brien EC, Sorenson C, Van Houtven CH. Amyloid-β PET Scan Results Disclosure and Care-Partner Emotional Well-Being Over Time. J Alzheimers Dis. 2022;90(2):775–782.

Published In

J Alzheimers Dis

DOI

EISSN

1875-8908

Publication Date

2022

Volume

90

Issue

2

Start / End Page

775 / 782

Location

Netherlands

Related Subject Headings

  • United States
  • Positron-Emission Tomography
  • Neurology & Neurosurgery
  • Medicare
  • Humans
  • Disclosure
  • Cognitive Dysfunction
  • Amyloidosis
  • Amyloid beta-Peptides
  • Amyloid